Tilatamig  (Synonyms: AZD9592 Antibody)

Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC)^[1].

Human Ig(G1-kappa_G1-lambda2)

Human IgG1 kappa, Isotype Control

Human

EGFR & MET

AZD9592 (8 mg/kg; single dose) induces dose-dependent DNA damage and apoptosis, and achieves tumor growth inhibition in 73% of EGFR mutant and 60% of EGFR wildtype NSCLC PDX models^[1].
AZD9592 (8 mg/kg; single dose) achieves tumor growth inhibition in 44% of HNSCC PDX models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1956  [NCBI] & 4233  [NCBI]

P00533 & P08581

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.77 kDa

2868265-50-1

Liquid

Colorless to light yellow

[Tilatamig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-lambda-kappa

• 
  Immobilized EGFR Protein, Human (sf9, His-GST, HY-P72987) can bind Tilatamig. The EC₅₀ for this effect is 945.9 ng/mL.
• 
  Immobilized HGFR Protein, Human (HEK293, His, HY-P70714) can bind Tilatamig. The EC₅₀ for this effect is 7.134 ng/mL.
• 
  Flow Cytometry analysis of Hela cells labelling EGFR (red) with Tilatamig (HY-P990947). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. McGrath L, et al. Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate[J]. Cancer Research, 2023, 83(7_Supplement): 5737-5737.